<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5002">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713735</url>
  </required_header>
  <id_info>
    <org_study_id>3393-1</org_study_id>
    <nct_id>NCT04713735</nct_id>
  </id_info>
  <brief_title>Impact of Lactoferrin, a Dietary Supplement, vs. Placebo on Respiratory Tract Infections</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Impact of Lactoferrin Dietary Supplementation on Respiratory Tract Infections in an Elderly Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mead Johnson Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to evaluate the impact of bovine&#xD;
      Lactoferrin (bLf) on respiratory tract infections (RTIs) in an elderly population in the&#xD;
      United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Respiratory Tract Infections</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Respiratory Tract Infection</measure>
    <time_frame>90 days</time_frame>
    <description>Mild, Moderate, or Severe rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Respiratory Tract Infection</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Respiratory Tract Infections</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment of Respiratory Tract Infections</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications from Respiratory Tract Infections</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microorganism causing Respiratory Tract Infection</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of protective antibody against influenza virus</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokine</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protection against apoptosis and oxidative stress</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary level of lactoferrin</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary level of thiocyanate</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary level of hypohalous acid</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Count</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive Metabolic Panel</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (12) Health Survey Version 2 (SF-12v2®)</measure>
    <time_frame>Baseline, Day 45 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of medical treatments</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically confirmed Adverse Events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID Vaccine specific inflammatory panel</measure>
    <time_frame>Day 45 and Day 90</time_frame>
    <description>IGG concentrations and geometric means of SARS psuedovirus neutralization titers and Cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Hemagglutination-inhibition Antibody Titer</measure>
    <time_frame>Pre-booster, Post-booster day 2, Post-booster day 7, and Post-booster day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Panel</measure>
    <time_frame>Pre-booster, Post-booster day 2, Post-booster day 7, and Post-booster day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Immune Health</condition>
  <arm_group>
    <arm_group_label>Control: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational: 600 mg bovine lactoferrin supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational: 600 mg bovine lactoferrin supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control: Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>bovine lactoferrin supplement</intervention_name>
    <description>600 mg</description>
    <arm_group_label>Investigational: 600 mg bovine lactoferrin supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 55 years of age at time of consent&#xD;
&#xD;
          -  Able to eat and drink, with assistance if required&#xD;
&#xD;
          -  Investigator and Community Living Center administration expect subject to reside in&#xD;
             Community Living Center for the duration of the study&#xD;
&#xD;
          -  Signed consent obtained from subject or legally authorized representative&#xD;
&#xD;
          -  Signed authorization obtained to use and/or disclose Protected Health Information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving (or, in the opinion of the Investigator, likely to receive in the next 6&#xD;
             months) parenteral nutrition&#xD;
&#xD;
          -  Have a known eating disorder or illness, which requires a therapeutic diet&#xD;
             incompatible with fortification and/or supplementation&#xD;
&#xD;
          -  Has been diagnosed as immunocompromised or is receiving medication which may cause&#xD;
             immune compromise. Note relative immunocompromisation due to age would not exclude the&#xD;
             subject&#xD;
&#xD;
          -  Known allergy or intolerance to study products&#xD;
&#xD;
          -  On an end-of-life care pathway or, in the opinion of the Investigator, has a life&#xD;
             expectancy of less than 6 months&#xD;
&#xD;
          -  Inappropriate for inclusion in the study in the opinion of the Investigator or&#xD;
             Community Living Center administration&#xD;
&#xD;
          -  Have experienced Respiratory Tract Infection within 1 week prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Wu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mead Johnson/RB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashlee Kirchoff</last_name>
    <phone>812-429-7997</phone>
    <email>ashlee.kirchoff@rb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Thames</last_name>
      <phone>310-825-0453</phone>
      <email>gthames@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zhaoping LI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

